Latest Regulatory Approvals News

Prescient Therapeutics reported a 62.8% increase in half-year losses to nearly $4 million, driven by intensified clinical development of its PTX-100 cancer therapy. The company bolstered its balance sheet with a $9.85 million capital raise while securing key regulatory milestones in Europe and the US.

Foresta Group Holdings reported a 12% increase in its half-year loss to nearly $2 million as it progresses its pioneering wood pellet and pine chemicals project in New Zealand, securing key lease agreements and finalising a $2.4 million insurance settlement.

TrivarX Limited reported a $1.26 million half-year loss as it completed the acquisition of Stabl-Im brain imaging IP and validated its mental health screening technology in veterans. The company raised $4.2 million to fund clinical development and expand its diagnostic portfolio.

Firebrick Pharma reports a reduced half-year loss of $1.26 million while launching its Nasodine Throat Spray in Singapore and Fiji, with regulatory approval pending in the Philippines.

Aeris Resources has reported a robust half-year performance with a 62% jump in profit, a successful $101.6 million equity raise, and a strategic divestment of North Queensland assets. The company also announced plans to acquire Peel Mining’s South Cobar Copper Project, signaling an aggressive growth trajectory.

Kelsian Group Limited has reported a robust first half for FY26 with double-digit revenue growth and upgraded EBITDA guidance, alongside a strategic $161 million sale of its Tourism Portfolio.

ClearView Wealth Limited has entered a definitive scheme implementation deed with Zurich Financial Services Australia Limited, agreeing to a $415 million acquisition at a 21.5% premium to its recent share price. The deal, supported by major shareholders and subject to regulatory and court approvals, offers shareholders a cash consideration of 65 cents per share plus potential dividends and ticking fees.

Greenwing Resources has significantly enhanced the economics of its Que River Project following a sharp rise in key metal prices, nearly doubling projected cash flows and advancing a two-stage development plan.

Catalina Resources has divested its Nelson Bay River iron ore project and secured a capital injection from Newcam Metals at a significant premium, bolstering its financial position for future exploration.

Ballymore Resources is progressing development at its high-grade Dittmer Gold Project with significant portal expansion, a 3,000-metre drilling program planned for Q2 2026, and trial mining of historic backfill and remnant pillars within a granted mining lease.

OncoSil Medical has reported record dose sales and cash receipts in the first half of FY26, supported by encouraging clinical trial results and expanded European market penetration.

Orthocell Limited has reported a record half-year revenue of $6.2 million, driven by accelerating sales of its regenerative medicine products and expanding global footprint. The company’s US commercial launch of Remplir™ is gaining momentum alongside new market entries in Canada, Hong Kong, and Europe.